ClinicalTrials.gg
RecruitingNCT07454174PKD-KETOUpdated Mar 6, 2026

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

An interventional study of Ren-Nu and KetoCitra in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Richard Fatica. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Richard Fatica · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Planned enrollment
50th of 63
20 · median 48
Started
2026
with 4 others
No phase
13 of 85
3 open now
Primary completion
2027-02
later than 10 of 24 live
Registered
83rd of 85
by date

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 50th largest by planned enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2026, is one of 13 with no phase, reaches primary completion later than 10 of the 24 other live ones, and was the 83rd registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.

Read the detailed description

The goal of the Ren-Nu program aims to improve the metabolic health of ADPKD patients by implementing a plant-focused, kidney-safe, ketogenic diet supported by medical food KetoCitra®. It is a dietitian-led, online group program focused on ketogenic metabolic therapy with rolling recruitment .

For 12 weeks, participants will be remotely directed through the Ren-Nu program by an experienced renal dietitian where they will learn to implement diet and lifestyle changes by completing weekly web-based classes on nutrition principles and food preparation. A continuous glucose monitor (CGM) will be provided for use during the study. Additionally, they will use a smartphone application to track nutrient intake, self-monitor biomarkers, implement mindfulness practice, and participate in facilitated discussions to build community support. Each participant will meet remotely with the renal dietitian and complete laboratory safety monitoring throughout the program to tailor dietary recommendations for optimal compliance. The study will involve visits to the research institution, histories, physical examinations and laboratory work.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

  • ADPKD
  • polycystic kidneys
  • Ren-Nu
  • KetoCitra
  • Keto diet
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (18 years or older)

    • Diagnosis of ADPKD by a physician.
    • Estimated (eGFR) ≥ 30 mL/min/1.73 m2 at screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
    • Appropriate control of blood pressure (i.e. entry reading \<140/90) including the use of BP medications for diagnosis of hypertension.
    • ≥ 25 (accounting for muscle mass)
    • Own an at-home blood pressure monitor (no brand requirements)
    • Able to complete study-related activities (e.g., attend online classes, complete questionnaires, and proper use of medical devices)

Exclusion criteria

Exclusion Criteria:

  • Intolerance or allergy to any of the ingredients in the provided medical food

    • Severe or rare underlying health conditions may cause a safety risk when taking the medical food. Those underlying health conditions will be assessed by the enrolling physician and include but are not limited to:

      • History of hyperkalemia
      • Heart failure
      • Liver cirrhosis
      • Chronic kidney disease stage 4 or greater, or other renal condition that severely impairs bone mineral homeostasis.
      • infection
      • Chronic drug or alcohol abuse
      • Chronic malabsorption syndrome
      • (non-melanoma skin cancer exempted)
      • disease
      • Pregnant, planning to be pregnant, or nursing during the course of the study
      • Chronic history of recurrent urinary tract infections (UTI) (≥ 3 UTIs per year)
      • Diagnosis of aneurysm
      • Indigestion due to hypochlorhydria (low stomach acid)
      • Any other condition, that in the opinion of the enrolling physician, makes the subject an unsuitable candidate for the study.
    • Current use of any of the following medications or supplements which could affect safety or compliance with this study:

      • The medical food, KetoCitra®.
      • Urine alkalizing agents such as sodium bicarbonate or potassium citrate
      • Citrate treatments
      • treatment
      • Tolvaptan
      • Potassium-sparing diuretics
      • Somatostatin analogs
      • Aluminum-containing supplements or medications such as aluminum antacids (e.g. Maalox) or aluminum-based phosphate binders.
      • SGLT2 inhibitors
    • Participation in another therapeutic intervention trial.
    • Following a highly specialized or extreme diet that is incompatible with the interventional nutrition program (e.g. carnivore, very high protein diet for elite athletes, etc.)
    • Food sensitivities or allergies that are incompatible with the interventional nutrition program.
    • The subject is already adhering to a form of a ketogenic diet or related fasting regimen.
    • Current or past history of disordered eating or feeding behaviors.
    • History of gastric bypass.
    • Active diagnosis of ulcerative colitis, Irritable Bowel Syndrome, Crohn's, or Gallbladder Disease.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Pilot study on ketogenic diet Ren-Nu and KetoCitra supplement on ADPKD

    Nutritional counseling and instruction in a ketogenic diet and nutritional food supplement

    Dietary Supplement: Ren-Nu and KetoCitra

Interventions

  • Dietary supplementRen-Nu and KetoCitra

    This is a structured, nutritionist monitored program supplemented with a nutritional food product, while monitoring metabolic parameters

    Also known as: Continuous glucose monitoring, intermittent fasting, Nutritional counseling

06

What researchers measure

Primary outcomes

  1. Change in Serum Renal Function

    Change from baseline of renal function assessment as measured by creatinine based estimated glomerular filtration rate.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  2. Change in Serum Hepatic Function Biomarkers

    Change from baseline of serum liver panel biomarkers to track safety signals. Biomarkers include: AST (U/L), ALT (U/L), and LDH (U/L). Measured via standard clinical laboratory assays.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  3. Change in Glycemic Control

    Change from baseline of glycemic control as measured by aggregate of Hgb A1c and Homeostatic model assessment of insulin resistance (HOMA-IR).

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  4. Change in Systemic Inflammation Markers

    Change from baseline of inflammatory biomarkers as an aggregate using: serum C-reactive protein \[(CRP) mg/dL\] and homocysteine (umol/L). Measured via standard clinical laboratory assays.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  5. Change in Serum Measures of Lipids

    Change from baseline of of lipids using fasting serum lipid panel to track cholesterol and fat levels. This includes: total cholesterol (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), and triglycerides (mg/dL).

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  6. Change in 24-Hour Urine Collection to track Lithogenic Risk

    Change from baseline of 24-hour urine analytes in aggregate to assess lithogenic risk. The analytes will include calcium (mg/day), creatinine (mg/day), citrate (mg/day), oxalate (mg/day), uric acid (mg/day), sodium (mmol/day), chloride (mmol/day), magnesium (mg/day), ammonium (mmol/day), sulfate (mmol/day), phosphorus (mg/day), urea nitrogen (g/day), and urine pH. Measured via standard clinical laboratory assays.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  7. Change in Glycemic Variability via a Continuous Glucose Monitor (CGM)

    Change from baseline in glycemic variability includes mean glucose (mg/dL) measured over a period of time and compared to before and at the end of the Ren-Nu program. This will be measured using the FreeStyle Libre 3 System.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  8. Change in Anthropometric Measures

    Change from baseline in body weight (kg) and body mass index (kg/m²), calculated from measured height and weight using standardized clinic procedures.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  9. Change in Blood Pressure

    Change from baseline in systolic and diastolic blood pressure. Seated blood pressure (mmHg) is taken throughout the 4 week orientation period and the 12 week nutritional dietary program. This is measured using a calibrated automated blood pressure machine after 5 minutes of rest.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  10. Change in Serum Fatty Acid

    Change from baseline of serum free fatty acid (FFA, mmol/L).

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

Secondary outcomes

  1. Change in health-related quality of life as assessed by the Quality of Life: Short-Form Health Survey 12 (SF-12v2)

    Participants will complete the Quality of Life: Short-Form Health Survey 12 (SF-12v2) on Day 0 and Day 120. Scores are standardized by mean. A higher score indicates a better-than-average health-related quality of life, while a lower score suggests a below-average health-related quality of life.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  2. Change in self reported mental and physical health outcomes

    This is reported as a change in participant reported mental health status measured via both the Quality of Life: Short-Form Health Survey 12 (SF-12v2) and the study-developed Ren-Nu Outcomes survey. The outcomes survey assesses topics such as final weight (kg), final blood pressure (mmHg), current PKD related symptoms, and changes to medications/supplements.

    Time frame: Visit 2 (Day 0) before Ren-Nu and Visit 3 (Day 120) after Ren-Nu

  3. Assessment of nutrition knowledge following the structured nutrition education program

    Self reported participant nutrition knowledge of the nutritional program at the end of the program. This is a study-developed questionnaire and these questions are multiple choice with a low score reflecting lower nutritional knowledge of the dietary program and a high score reflecting higher nutritional knowledge of the dietary program.

    Time frame: Visit 3 (Day 120) after Ren-Nu

  4. Assessment of dietary intervention tolerability following the structured nutrition education program

    Self reported participant tolerability of the nutritional program at the end of the program. This is a study-developed questionnaire and questions are multiple choice with a low score reflecting a lower tolerability to the dietary program and a high score reflecting higher satisfaction with the program.

    Time frame: Visit 3 (Day 120) after Ren-Nu

  5. Assessment of dietary intervention feasibility following the structured nutrition education program

    Self reported participant feasibility of the nutritional program at the end of the program. This is a study-developed questionnaire and questions are multiple choice with a low score reflecting lower feasibility of the dietary program and a high score reflecting higher feasibility of the dietary program.

    Time frame: Visit 3 (Day 120) after Ren-Nu

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 23 interventional studies with no phase under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 54. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Mar 6, 2026
StartActual
Feb 25, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2028
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07454174
Lead sponsor
Richard Fatica
Collaborators
Santa Barbara Nutrients
Responsible party
Richard Fatica (Vice Chairman Department of Kidney Medicine, The Cleveland Clinic) — Sponsor-investigator
First posted
Mar 6, 2026
Start date
Feb 25, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Mar 6, 2026

Study contacts

Chloe Booth
Contact
boothc2@ccf.org
216-444-5053
Richard Fatica, MD
Contact
faticar@ccf.org
216-445-9953
Richard Fatica, MD
principal investigator · The Cleveland Clinic
Thomas Weimbs, PhD
study director · Santa Barbara Nutrients

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion